Hydrochloric Acid

Hydrochloric Acid

SCHEMBL2255171

CCOC(=O)C(C)N.[Cl-].[H+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5202071 1.00
SCHEMBL196408 0.95
SCHEMBL372610 0.95
SCHEMBL135308 0.95
Hydrochloric Acid SCHEMBL135306 0.92
Hydrochloric Acid SCHEMBL135307 0.92
Hydrochloric Acid SCHEMBL842523 0.92
Bromide SCHEMBL5401276 0.92
Bromide SCHEMBL5401279 0.92
Water SCHEMBL28328236 0.92

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113552265-B Method for detecting impurities in raw materials for synthesizing propane fumarate tenofovir and application 天地恒一制药股份有限公司 2022-01-04 CN disclosed
CN-113552265-A Method for detecting impurities in raw materials for synthesizing propane fumarate tenofovir and application 天地恒一制药股份有限公司 2021-10-26 CN disclosed
EP-3219335-B1 COATING COMPOSITION AND MEDICAL DEVICE TERUMO CORP (JP) 2018-12-19 EP disclosed
EP-3219335-A1 COATING COMPOSITION AND MEDICAL DEVICE Terumo Kabushiki Kaisha (JP) 2017-09-20 EP disclosed
WO-2017102802-A1 RESORCINOL DERIVATIVES FOR THEIR COSMETIC USE L'OREAL (FR) 2017-06-22 WO disclosed
US-20170143663-A1 COATING COMPOSITION AND MEDICAL DEVICE TERUMO KABUSHIKI KAISHA (JP) 2017-05-25 US disclosed
US-9603974-B2 Coating composition and medical device TERUMO KABUSHIKI KAISHA (JP) 2017-03-28 US disclosed
US-9592322-B2 Coating composition and medical device TERUMO KABUSHIKI KAISHA (JP) 2017-03-14 US disclosed
EP-2801379-B1 COATING COMPOSITION AND MEDICAL DEVICE TERUMO CORP (JP) 2017-03-08 EP disclosed
US-20150057746-A1 COATING COMPOSITION AND MEDICAL DEVICE TERUMO KABUSHIKI KAISHA (JP) 2015-02-26 US disclosed
US-20150056265-A1 COATING COMPOSITION AND MEDICAL DEVICE TERUMO KABUSHIKI KAISHA (JP) 2015-02-26 US disclosed
EP-2234978-B1 CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 ASTRAZENECA AB (SE) 2015-02-25 EP disclosed
EP-2801379-A1 COATING COMPOSITION AND MEDICAL DEVICE Terumo Kabushiki Kaisha (JP) 2014-11-12 EP disclosed
CN-101932562-B Carbamoyl compounds as dgat1 inhibitors 190 ASTRAZENECA AB 2013-06-12 CN disclosed
US-20120108602-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2012-05-03 US disclosed
US-7994179-B2 Carbamoyl compounds as DGAT1 inhibitors 190 ASTRAZENECA AB (SE) 2011-08-09 US disclosed
CN-101932562-A Carbamoyl compounds as dgat1 inhibitors 190 ASTRAZENECA AB 2010-12-29 CN disclosed
EP-2234978-A1 CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 AstraZeneca AB (SE) 2010-10-06 EP disclosed
US-20090298853-A1 Carbamoyl Compounds as DGAT1 Inhibitors 190 ASTRAZENECA AB (SE) 2009-12-03 US disclosed
WO-2009081195-A1 CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190 ASTRAZENECA AB (SE) 2009-07-02 WO disclosed